Organisation paid for research Program year 2025 Source: CMS Open Payments

Calneuro Research Group

Neither a doctor nor a teaching hospital

Research payments

$671,716

57 payments

Through program year 2025, Calneuro Research Group is reported as receiving $671,716 in research payments, across 57 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $10,338 4
2024 Research $25,914 4
2023 Research $187,003 11
2022 Research $138,048 15
2021 Research $237,836 20
2020 Research $28,184 2
2019 Research $44,393 1

Breakdown

Who paid Research payments · program years 2019–2025
  1. Janssen Research & Development, LLC $282,646 25 payments
  2. Otsuka Pharmaceutical Development & Commercialization, Inc. $154,810 11 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $96,028 3 payments
  4. Biohaven Pharmaceuticals, Inc. $73,208 7 payments
  5. Biohaven Pharmaceutical Holding Company Ltd. $30,151 2 payments
  6. Boehringer Ingelheim Pharma GmbH & Co.KG $17,175 3 payments
  7. ITI, Inc. $10,338 4 payments
  8. Avanir Pharmaceuticals, Inc. $6,520 1 payment
  9. AbbVie, Inc. $840 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression $282,646 25 payments
  2. PoCC study in patients with PTSD $113,202 6 payments
  3. A Randomized Double-Blind Placebo-Controlled Trial of Adjunctive Troriluzole in Obsessive Compulsive Disorder $83,619 6 payments
  4. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole As Adjunctive Therapy in the Maintenance Treatment of Adults With Major Depressive Disorder. $70,249 3 payments
  5. A Multicenter, Randomized, Flexible-Dose, Double Blind Trial of Brexpiprazole Versus Placebo for the Treatment of Adults With Borderline Personality Disorder $35,038 2 payments
  6. A Phase 3, Multicenter, Randomized, Double-Blind Trial of Fixed-Dose Brexpiprazole As Combination Therapy With Sertraline in the Treatment of Adults With Post-Traumatic Stress Disorder $20,546 2 payments
  7. A Multicenter 48-week Open-Label Safety Study of Adjunctive Troriluzole in Subjects with Obsessive Compulsive Disorder $19,740 3 payments
  8. A Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Brexpiprazole $11,715 1 payment
  9. A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder Who Have an Inadequate Response to Generalized Anxiety Disorder Treatment $10,338 4 payments
  10. A Phase Iiib Multi-Center, Open-Label, Mirror-Image, Study in Adult Subjects With Schizophrenia Treated Prospectively for 6-Months With Abilify Mycite $10,057 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record